Navigation Links
Study Shows Bacterial Contamination Associated With Home-Laundered Surgical Scrubs Is Significantly Greater Than Other Options
Date:1/8/2010

NORCROSS, Ga., Jan. 8 /PRNewswire/ -- A study comparing the aerobic bacterial bioburden associated with surgical scrub attire shows significantly greater contamination among home-laundered attire than scrubs laundered by the healthcare facility, scrubs sent out by the facility to a third-party company for laundering, or single-use/disposable scrubs. In fact, home-laundered scrubs cleaned and ready to wear had as much bacteria present as facility-laundered, third-party laundered and single-use scrubs which had been worn for one day.

Conducted in the spring of 2009, the study was performed by Bioscience Laboratories, Inc., of Bozeman, Mont., and sponsored by Molnlycke Health Care US, LLC. A total of 80 surgical scrub garments, tops and bottoms, prior to use and after use in the operating room for a day, were collected from multiple healthcare facilities across the U.S. They comprised 10 sets of scrubs in each category: single-use; home-laundered; facility-laundered; and third-party laundered.

The study showed no statistically significant difference in bacterial contamination among facility-laundered, third-party laundered or single-use scrubs prior to use ("clean"), but revealed that the bioburden found on home-laundered scrubs prior to use ("clean") was significantly greater than on any of the other garments (facility-laundered, third-party laundered or single-use, non-woven) that had been worn for a day in the operating room.

"According to these results, a healthcare professional beginning his or her shift in home-laundered scrubs would essentially be wearing scrubs with the same quantity of bacteria as the scrubs of a healthcare professional finishing a shift in worn scrubs," said Heather Beitz, BA MEd, Director of Clinical Research for Molnlycke Health Care.

"This study indicates that home-laundering is not as effective as facility- or third-party laundering in decontaminating surgical scrub attire," Beitz explained. "Another option, of course, is single-use surgical attire. In addition to eliminating cross-contamination concerns as indicated in this study, single-use scrubs are durable and designed for daily use in a variety of surgical procedures and acute care needs and can reduce replacement costs," she added.

BARRIER® surgical scrub suits and jackets, manufactured by Molnlycke Health Care, are non-woven, single-use products that provide comfort with the soft feel of cotton. They are available in extended size ranges (S - 4XL), assuring a variety of fits. Departments benefiting from the use of BARRIER non-woven scrubs and jackets are trauma, isolation, ER, NICU (for parents), L&D (for fathers), cath and GI labs, oncology, and radiology/interventional radiology.

About Molnlycke Health Care US, LLC

Molnlycke Health Care US, LLC, consists of two divisions - Surgical and Wound Care. Focusing on prevention of surgically-related infections for both patients and healthcare workers, the Surgical Division (formerly Regent Medical Americas, LLC) encompasses the world's leading manufacturer and supplier of powder-free surgical gloves (Biogel® surgical gloves); the number one supplier (by value) of skin cleanser (Hibiclens® and Hibistat® antiseptics); and BARRIER® protective clothing. A leader in trauma and pain management, the Wound Care Division's market dynamics are driven by an aging population, higher incidence of pressure ulcers and increased home treatment.

SOURCE Molnlycke Health Care US, LLC


'/>"/>
SOURCE Molnlycke Health Care US, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):